Literature DB >> 25251994

Intraclass differences among antihypertensive drugs.

R D Feldman1, Y Hussain, L M Kuyper, F A McAlister, R S Padwal, S W Tobe.   

Abstract

The four major classes of antihypertensive drugs—diuretics, β-blockers, calcium channel blockers, and renin-angiotensin system inhibitors (including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers)—have significant qualitative and quantitative differences in the adverse effects they cause. Structural and chemical differences have been identified within these classes, especially among the calcium channel blockers and, to a lesser extent, among the thiazide/thiazide-like diuretics. However, it has been more difficult to demonstrate that these differences translate into differential effects with respect to either the surrogate endpoint of blood pressure reduction or, more importantly, hypertension-related cardiovascular complications. Based on a hierarchy-of-evidence approach, differences are apparent between hydrochlorothiazide and chlorthalidone based on evidence of moderate quality. Low-quality evidence suggests atenolol is less effective than other β-blockers. However, no significant intraclass differences have been established among the other classes of antihypertensive drugs.

Entities:  

Keywords:  angiotensin receptor blockers; angiotensin-converting enzyme inhibitors; calcium channel blockers; diuretics; hypertension; β-blockers

Mesh:

Substances:

Year:  2014        PMID: 25251994     DOI: 10.1146/annurev-pharmtox-010814-124446

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  5 in total

1.  Pharmacovigilance database search discloses ClC-K channels as a novel target of the AT1 receptor blockers valsartan and olmesartan.

Authors:  Paola Imbrici; Domenico Tricarico; Giuseppe Felice Mangiatordi; Orazio Nicolotti; Marcello Diego Lograno; Diana Conte; Antonella Liantonio
Journal:  Br J Pharmacol       Date:  2017-04-26       Impact factor: 8.739

2.  Renal secretion of hydrochlorothiazide involves organic anion transporter 1/3, organic cation transporter 2, and multidrug and toxin extrusion protein 2-K.

Authors:  Jia Yin; David J Wagner; Bhagwat Prasad; Nina Isoherranen; Kenneth E Thummel; Joanne Wang
Journal:  Am J Physiol Renal Physiol       Date:  2019-07-19

3.  Acute and chronic cardiometabolic responses induced by resistance training with blood flow restriction in HIV patients.

Authors:  Thiago Cândido Alves; Pedro Pugliesi Abdalla; Lucimere Bohn; Leonardo Santos Lopes Da Silva; André Pereira Dos Santos; Márcio Fernando Tasinafo Júnior; Ana Cláudia Rossini Venturini; Jorge Mota; Dalmo Roberto Lopes Machado
Journal:  Sci Rep       Date:  2022-10-10       Impact factor: 4.996

4.  Pharmacogenetic Risk Stratification in Angiotensin-Converting Enzyme Inhibitor-Treated Patients with Congestive Heart Failure: A Retrospective Cohort Study.

Authors:  Karl Emil Nelveg-Kristensen; Majbritt Busk Madsen; Christian Torp-Pedersen; Lars Køber; Martin Egfjord; Henrik Berg Rasmussen; Peter Riis Hansen
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

5.  Pharmacodynamic Impact of Carboxylesterase 1 Gene Variants in Patients with Congestive Heart Failure Treated with Angiotensin-Converting Enzyme Inhibitors.

Authors:  Karl Emil Nelveg-Kristensen; Peter Bie; Laura Ferrero; Ditte Bjerre; Niels E Bruun; Martin Egfjord; Henrik B Rasmussen; Peter R Hansen
Journal:  PLoS One       Date:  2016-09-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.